CompanyGraph
Inner Mongolia Furui Medical Science Co., Ltd.
300049 · SZSE · China
fu-rui.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.89B, above the global median of $1.18B
- FinancialsAltman Z-Score 9.39: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.03%
Annual Rate
CNY 0.01Paid unknown
Payout Ratio
24.2%Sustainable
Last Ex-Dividend
Jul 6, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.64BCNY1.89B · vs all stocks (USD)
Trailing P/E
77.24xvs Biotechnology peers
Revenue (TTM)
1.64BCNY244.24M · vs all stocks (USD)
Profit Margin
10.15%vs Biotechnology peers
Beta
-0.2950xvs all stocks
52-Week Change
-40.29%vs all stocks
Market Capitalization
12.64BCNY1.89B · vs all stocks (USD)
Enterprise Value
12.57BCNY1.88B · vs all stocks (USD)
Trailing P/E
77.24xvs Biotechnology peers
Forward P/E
35.21xvs Biotechnology peers
Price to Sales (TTM)
7.72xvs Biotechnology peers
Price to Book (MRQ)
6.43xvs Biotechnology peers
Enterprise to Revenue
7.68xvs Biotechnology peers
Enterprise to EBITDA
25.39xvs Biotechnology peers
Gross Margin
76.56%vs Biotechnology peers
Profit Margin
10.15%vs Biotechnology peers
Operating Margin
21.45%vs Biotechnology peers
Return on Assets (TTM)
7.77%vs Biotechnology peers
Return on Equity (TTM)
12.48%vs Biotechnology peers
Revenue (TTM)
1.64BCNY244.24M · vs all stocks (USD)
Revenue per Share (TTM)
6.08CNYUpdated Sep 20, 2026Quarterly Revenue Growth
3.00%vs Biotechnology peers
Gross Profit (TTM)
1.23BCNY183.53M · vs all stocks (USD)
EBITDA (TTM)
347.85MCNY51.91M · vs all stocks (USD)
Net Income (TTM)
166.10MCNY24.78M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
38.00%vs Biotechnology peers
Operating Cash Flow (TTM)
393.43MCNY58.71M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
397.43MCNY59.30M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0150CNYUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.03%vs all stocks
Payout Ratio
24.19%vs Biotechnology peers
Minority Interest (Equity)
493.26MCNYFY2025 · Dec 31, 2025Revenue
1.60BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
399.36MCNYFY2025 · Dec 31, 2025Gross Profit
1.20BCNYFY2025 · Dec 31, 2025Operating Income
399.40MCNY59.60M · vs all stocks (USD)
Pre-tax Income
350.56MCNYFY2025 · Dec 31, 2025Income Tax Expense
92.14MCNYFY2025 · Dec 31, 2025Net Income
258.42MCNYFY2025 · Dec 31, 2025EBIT
353.79MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
461.30MCNYFY2025 · Dec 31, 2025Research & Development
111.20MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
171.86MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.99MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
19.29MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.22MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5800CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
265.67MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
265.67MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
258.42MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-104.33MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
165.48MCNYFY2025 · Dec 31, 2025Free Cash Flow
-19.08MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
640.28MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
258.42MCNYFY2025 · Dec 31, 2025Other Non-cash Items
38.78MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-120.63MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-11.09MCNYFY2025 · Dec 31, 2025Capital Expenditures
-184.56MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.37BCNYFY2025 · Dec 31, 2025Sale of Investments
1.37BCNYFY2025 · Dec 31, 2025Other Investing Activity
-28.70MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-213.03MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
12.40MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-2.29MCNYFY2025 · Dec 31, 2025Other Financing Charges
-59.70MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-49.58MCNYFY2025 · Dec 31, 2025Shares Outstanding
263.99MSharesUpdated Sep 20, 2026Float Shares
202.76MSharesUpdated Sep 20, 2026% Held by Insiders
24.57%vs all stocks
% Held by Institutions
12.65%vs all stocks
Total Cash (MRQ)
737.75MCNY110.09M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.79CNYUpdated Sep 20, 2026Total Debt (MRQ)
150.12MCNY22.40M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0604xvs Biotechnology peers
Current Ratio (MRQ)
3.17xvs Biotechnology peers
Book Value per Share (MRQ)
7.45CNYUpdated Sep 20, 2026Total Assets
3.44BCNY513.15M · vs all stocks (USD)
Total Current Assets
1.54BCNYFY2025 · Dec 31, 2025Total Liabilities
967.33MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.89BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
485.08MCNYFY2025 · Dec 31, 2025Total Current Liabilities
482.25MCNYFY2025 · Dec 31, 2025Cash
640.02MCNYFY2025 · Dec 31, 2025Cash Equivalents
9.72MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
649.74MCNYFY2025 · Dec 31, 2025Other Short-term Investments
83.62MCNYFY2025 · Dec 31, 2025Accounts Receivable
445.27MCNYFY2025 · Dec 31, 2025Inventory
148.97MCNYFY2025 · Dec 31, 2025Accounts Payable
128.75MCNYFY2025 · Dec 31, 2025Short-term Debt
106.55MCNYFY2025 · Dec 31, 2025Other Current Liabilities
12.82MCNYFY2025 · Dec 31, 2025Long-term Debt
69.43MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
4.18MCNYFY2025 · Dec 31, 2025Common Stock (Book)
264.98MCNYFY2025 · Dec 31, 2025Retained Earnings
915.91MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.47BCNY368.81M · vs all stocks (USD)
Treasury Stock
34.78MCNYFY2025 · Dec 31, 202552-Week Low
36.50CNYUpdated Sep 20, 202652-Week High
86.90CNYUpdated Sep 20, 202652-Week Change
-40.29%vs all stocks
Beta
-0.2950xvs all stocks
50-Day MA
43.57CNYUpdated Sep 20, 2026200-Day MA
54.99CNYUpdated Sep 20, 2026Avg 10-Day Volume
8.74MSharesUpdated Sep 20, 2026Avg 30-Day Volume
9.12MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.6200CNYUpdated Sep 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 9.39: safe zoneNotable
Altman Z-Score: 9.39
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.89B, above the global median of $1.18BNotable
Market cap (USD): 1,886,518,890.502Global Median: 1,180,223,658.953
Levered free cash flow is $59.3M, above the global median of $18.73MNotable
Levered free cash flow (USD): 59,303,905.332Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xencor Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Fagron NV
Tier 1ProductionApproval-Gated PipelineFlowRule
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
ChemoMetec A/S
Tier 1ProductionApproval-Gated PipelineRule
Cofoe Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jinyu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
MeHow Innovative Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Genus Power Infrastructures Ltd.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated
Grupo Mateus S.A.
1 interpretationMulti-Year Revenue, Profit, And Income Growth
Grupo Herdez S.A.B. de C.V.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated